Skip to main content
. 2020 Nov 23;10:563407. doi: 10.3389/fonc.2020.563407

Table 3.

Second line chemotherapy for patients with BRAFV600E mutated colorectal cancer.

Regimen Partial response Stable disease Progression disease mPFS (months)
VIC (N = 8) 1 5 2 2.9
Bevacizumab + FOLFOXIRI/FOLFIRI (N = 8) 1 4 3 9.7
FOLFOXIRI/FOLFIRI (N = 2) 0 0 2 1.2
Regorafenib/Fruquintinib (N = 3) 1 1 1 1.8